Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

Inclusion Criteria:

Subjects who completed the TERMS study and received at least 1 study treatment injection
Signed and dated statement of informed consent

Exclusion Criteria:

Pregnancy or breastfeeding
Experienced a serious adverse drug reaction with confirmatory relationship to Tovaxin in the TERMS study.
Withdrew from TERMS study and did not continue participating in the remaining 52-week core TERMS study assessments.
Non-compliant with TERMS study.
Diagnosis of progressive-relapsing, secondary progressive or primary progressive Multiple Sclerosis (MS) while enrolled in the TERMS study.
Medical, psychiatric or other conditions that compromise the subject's ability to give informed consent, to understand the patient information, to comply with the study protocol, or to complete the study.
Any significant change in the subject's medical condition after enrollment in the TERMS study which would have lead to his/her exclusion from participation in that study.